A peripherally acting biarylpyrazole CB1 antagonist, namely, AM6545, developed in our laboratory, was shown to be a safer alternative to rimonabant for treating metabolic disorders [11,12,13]. This evidence concerns the gene CNR1 and metabolic disease.